Proton-Based Stereotactic Ablative Radiotherapy in Early-Stage Non-Small-Cell Lung Cancer

Table 2

Summary of clinical data for proton-based stereotactic ablative and hypofractionated radiotherapy.

Author, reference	Years	Number of cases (T1/T2)	Total dose, GyE; (dose per fraction)	Local; control	Overall; survival	Toxicity grade ≥3
Bush et al., [30]	Unknown	111 (47/64)	51/60/70 (5.1/6/7)	4 yr, 45/75/86/91%*	4 yr, 18/32/51%^†	None
Hata et al., [31]	2002–2005	21 (11/10)	50–60 (5-6)	2 yr, 95%	2 yr, 74%	RP 4%
Nakayama et al., [32]	2001–2008	58 (30/28)	66-peripheral/72.6-central (6.6/3.3)	2 yr, 97%	2 yr, 98%	RP 4%
Nihei et al., [33]	1999–2003	37 (17/20)	70–94 (3.5–4.9)	2 yr, 98%	2 yr 84%	RP 8%
Iwata et al., [35]	2003–2007	57 (27/30)	60/80 (6/4)	3 yr, 83/81%^‡	3 yr, 60/90%^‡	RP 2%, dermatitis 5%
Iwata et al., [36]	2003–2009	43 (0/43)	60/66/70.2/80 (6/6.6/2.7/4)	3 yr, 75%	3 yr, 78%	RP 3%, dermatitis 7%§
Fujii et al., [37]	2003–2009	70 (36/34)	60/80 (6/4)	3 yr, 81%	3 yr, 72%	RP 0%, dermatitis 4%, rib fracture 1%^‖
Westover et al., [38]	2008–2010	20 (18/2)	42–50 (10–16)	2 yr, 100%	2 yr, 64%	RP 7%

∗Reported for the following groups: (T2, 60 GyE)/(T2, 70 GyE)/(T1, 60 GyE)/(T1, 70 GyE), ^†Reported for: 51 GyE/60 GyE/70 GyE. ^‡Reported for 60/80 GyE. §Toxicity data includes 27 combined patients treated with carbon ion therapy, which were not separated in the manuscript. ‖Termed late toxicity, time period not defined. RP: radiation pneumonitis.